Capstone Turbine (CPST) Prices $7.5M Offering of Common Stock and Warrants

October 18, 2016 9:27 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Capstone Turbine Corporation (Nasdaq: CPST) announced today that it has agreed to sell 6.3 million shares of the Company’s common stock (“Common Stock”) to one existing and one new accredited investor in a registered offering. The Company will issue 3.6 million shares of Common Stock and pre-funded Series B warrants to purchase an additional 2.7 million shares of Common Stock to the purchasers, one of whose purchase of Common Stock in the offering otherwise would result in the purchaser beneficially owning more than 9.99% of the Company’s outstanding Common Stock following the completion of the offering (“Series B Warrants”). Each share of Common Stock will be sold at a price of $1.20. Each Series B Warrant will have an exercise price of $1.20 per share of Common Stock, $1.19 of which will be pre-funded at closing and $0.01 of which will be payable upon exercise of the warrant.

Concurrently with the registered offering of Common Stock and Series B Warrants, the Company is conducting a private placement of Series A warrants to purchase up to 6.3 million shares of Common Stock to the purchasers of Common Stock and Series B Warrants in the registered offering (“Series A Warrants”). Each Series A Warrant will have an exercise price of $1.34 per share of Common Stock.

Oppenheimer & Co. Inc. acted as the lead placement agent and Roth Capital Partners acted as co-placement agent.

"We appreciate the support of our investors as we continue to pursue several larger multi-megawatt projects. Maintaining a strong balance sheet is critical to our business," said Darren Jamison, Capstone’s President and Chief Executive Officer.

The gross proceeds to the Company from the offering are expected to be approximately $7.5 million and the net proceeds to the Company from the offering, after deducting the placement agent fees and other estimated offering expenses, are expected to be approximately $6.8 million, in each case without giving any effect to any exercise of the Series B Warrants or any sale or exercise of the Series A Warrants. The Company intends to use the proceeds from the offering to fund general working capital requirements and for other general corporate purposes. The offering is expected to close on or about October 21, 2016, subject to the satisfaction of customary closing conditions.

The Common Stock, the Series B Warrants and the Common Stock issuable upon exercise of the Series B Warrants are being offered pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-203431). The registered portion of the offering will be made by means of a prospectus supplement and accompanying base prospectus. When available, copies of the final prospectus supplement and accompanying base prospectus related to the registered portion of the offering (the “Offering Documents”) may be obtained from the Securities and Exchange Commission’s website at http://www.sec.gov. When available, electronic copies of the Offering Documents may also be obtained from Oppenheimer & Co. Inc., 85 Broad Street, 26th Floor, New York, NY 10004, Attn: Syndicate Prospectus Department, by calling (212) 667-8563, or by email to EquityProspectus@opco.com.

The Series A Warrants and the Common Stock issuable upon exercise of the Series A Warrants are not being registered under the Securities Act of 1933, as amended (the “Securities Act”), are not being offered pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-203431) or by means of the Offering Documents, and are being offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Equity Offerings

Related Entities

Roth Capital, S3

Add Your Comment